SCHEMBL860184

SCHEMBL860184

O=C1NC(=O)C(=Cc2cnn3ccc(Nc4ccc(Cl)cc4)nc23)S1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.49
PIM2 Q9P1W9 3/20 0.49
IGF1R P08069 2/20 0.44
NR1H4 Q96RI1 1/20 0.42
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
PLA2G1B P04054 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
JAK3 P52333 2/20 0.41
MYC P01106 1/20 0.40
NAT1 P18440 1/20 0.40
MAX P61244 1/20 0.40
GSK3B P49841 1/20 0.40
MGAM O43451 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12768720 1.00 PIM1 (0.49) PIM1PIM2IGF1RNR1H4HTT
SCHEMBL860183 1.00 PIM1 (0.49) PIM1PIM2IGF1RNR1H4HTT
SCHEMBL861502 0.89 PIM1 (0.49) PIM1PIM2IGF1RNR1H4HTT
SCHEMBL861503 0.89 PIM1 (0.49) PIM1PIM2IGF1RNR1H4HTT
SCHEMBL12978877 0.89 PIM1 (0.49) PIM1PIM2IGF1RNR1H4HTT
SCHEMBL860452 0.82 GSK3B (0.42) PIM1HPGDLMNAPOLBGSK3B
SCHEMBL12979564 0.82 GSK3B (0.42) PIM1HPGDLMNAPOLBGSK3B
SCHEMBL860453 0.82 GSK3B (0.42) PIM1HPGDLMNAPOLBGSK3B
SCHEMBL3483094 0.81 NR1H4 (0.43) PIM1PIM2NR1H4NPC1RAB9A
SCHEMBL12978963 0.81 NR1H4 (0.43) PIM1PIM2NR1H4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2475652-A1 PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS Cylene Pharmaceuticals, Inc. (US) 2012-07-18 EP disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20110071115-A1 PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS CYLENE PHARMACEUTICALS, INC. (US) 2011-03-24 US disclosed
WO-2011031979-A1 PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS CYLENE PHARMACEUTICALS INC. (US) 2011-03-17 WO disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071115-A1 PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS PIM2, PIM1, PIM3 PIM1 2/4885PIM2 1/4885IGF1R 718/4885
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885IGF1R 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.